The US Food and Drug Administration opened a public consultation on generative AI-enabled medical devices on August 18, 2026. Its discussion paper treats autonomous action, tool use and reduced opportunities for human review as distinct risks, but it creates no new rule.
The International Medical Device Regulators Forum published final principles for planned medical-software changes on August 6, 2026. The framework puts updates inside a workflow that begins with intended use and data, then moves through validation, human review and monitoring.
The US Office of the National Coordinator for Health Information Technology updated its electronic health record explainer on December 10, 2025. Medical AI still needs separate checks for data meaning, access, workflow and responsibility before exchanged records can support a deployed system.
Australia will expand its Pharmaceutical Benefits Scheme listing for pembrolizumab on September 1, 2026, adding three cancer indications. The government expects about 700 people a year to benefit, but access will depend on the Australian scheme's prescribing conditions.
The International Medical Device Regulators Forum made representative data, independent testing and post-deployment monitoring part of its 2025 medical AI principles. Hospitals can turn those principles into subgroup tests that report uncertainty, site effects and failure costs instead of relying on one overall score.
The International Medical Device Regulators Forum finalized 10 good machine learning practice principles for medical AI in January 2025. The framework links intended use, data, human-AI testing and monitoring, but it does not assign legal fault after an incident.
The International Medical Device Regulators Forum finalized 10 good machine learning practice principles for AI-enabled medical devices on January 27, 2025. The framework makes representative data, independent testing, human-AI interaction and post-deployment monitoring part of one evidence chain.
The International Medical Device Regulators Forum finalized 10 lifecycle principles for medical AI in January 2025. They show why access to insurance claims data does not by itself establish data quality or clinical performance.
Taiwan's Ministry of Health and Welfare launched a medical informatics certification laboratory on August 18, 2026, to develop tests around its FHIR Box health-data integration program. The planned checks cover software, hardware and solution providers, but interoperability does not establish data quality or clinical performance.
A 2025 Science Advances study found that low-dose metformin's glucose-reducing effect in mice depended on a brain Rap1 pathway. The evidence comes from experimental animals, and the parallel for medical AI is limited: a plausible explanation cannot replace external and clinical validation.
The World Health Organization's 2025 ICOPE handbook places in-depth assessment, care planning, implementation and monitoring after a basic capacity screen. Its pilot data show why services need to record each handoff rather than report only the number of people screened.
Taiwan's health ministry launched the National Medical Informatics Certification Laboratory on August 18, 2026. Its three planned tracks cover software, FHIR Box hardware and solution providers, but interoperability tests do not establish clinical safety for medical AI.
The US Food and Drug Administration replaced its medical-device cybersecurity guidance in February 2026, updating recommendations tied to statutory duties that took effect in 2023. Taiwan's regulator publishes a 2021 lifecycle guide and five reference templates, but the cited public material does not establish a US-style statutory submission rule.
The World Health Organization's 2025 ICOPE handbook places a six-area capacity screen at the start of a four-stage primary care pathway for older adults. Studies in Spain and Taiwan found that results varied by domain and tool version, limiting what a one-time screen can establish.
Shionogi launched ENDEAVORRIDE in Japan on June 5, 2026 after Japanese regulators reviewed local and US clinical data. The company also holds Taiwan rights, but APPI News could not verify a Taiwan license or public filing.
The US Centers for Medicare & Medicaid Services published a final rule on August 13 that ends federal matching funds for specified gender-affirming treatments on October 13. States may finance them separately, while a six-month federal transition applies only to people already receiving cross-sex hormone therapy.
A 2025 systematic review found that all six included studies, covering 689 children, reported gains in at least one developmental domain. No randomized trials were included, and WHO-UNICEF guidance says a concerning screen must lead to assessment and tracked follow-up rather than serve as a diagnosis.
US President Donald Trump signed an executive order on August 10 recognizing an 11-disease core childhood immunization list and calling for separate measles, mumps and rubella shots. Separate products are not currently available in the United States, while state school mandates do not change automatically.
The US Food and Drug Administration cleared AEYE-DS for use with the handheld Optomed Aurora retinal camera on April 23, 2024. The system automatically returns a screening result, but its authorization and performance data have defined limits.
The US Food and Drug Administration announced its first TEMPO participant on July 22, 2026 and now lists two manufacturers in the pilot. Their devices can enter Medicare-supported care through conditional enforcement discretion and real-world data collection, not a finding of effectiveness for the uses under review.
The US Senate confirmed Erica Schwartz as director of the Centers for Disease Control and Prevention in a 51-44 vote on August 5. She takes over after repeated leadership changes and the loss of more than one-quarter of the agency's workforce.
UC San Diego researchers reported on July 8, 2026, that a surgeon remotely controlled a humanoid robot during two gallbladder operations on pigs. The study showed technical feasibility, but human bedside assistance, repeated recalibration and sterility problems remain barriers to clinical use.
Researchers in South Korea and the United States reported two manufacturing advances for stretchable electronics in 2026. One kept liquid-metal conductors working under repeated strain, while the other put a dense computing array on a stretchable patch, but neither study tested a finished implant in people.
A systematic review published in January 2026 found that generative AI increased the volume, speed and perceived credibility of health misinformation in the available studies. Clinicians can use the same tools to draft public information, but the evidence and professional guidance leave accuracy, privacy and disclosure with the person who publishes it.
A July 30, 2026 Coldcard advisory showed how a random-number integration error could remain hidden while security-sensitive outputs still looked valid. The same failure pattern matters in health information systems that generate pseudonyms and SMART on FHIR authorization secrets.
A September 2025 paper argued that language-model training and widely used benchmarks reward guessing over acknowledging uncertainty. A 2026 health-chatbot audit found 49.6 percent of answers problematic, showing how fluent errors can reach high-stakes uses.
Rwanda is expanding a medical drone network that has carried blood and other supplies since 2016. Faster deliveries can reduce delays and waste, but reporting from rural facilities shows that aircraft cannot supply missing staff, equipment or continuing care.
AI-designed drug candidates have moved into mid- and late-stage trials, but APPI News found no publicly identified US approval for a novel drug originating from an AI-led discovery program as of August 4, 2026. Early data point to faster candidate selection and stronger Phase 1 results, while later trials still impose the usual tests of safety and efficacy.
Taiwan's national health insurer is targeting older adults who use three or more sleeping medicines for extended periods. The review combines prescription oversight with sleep assessments, while evidence links some sedative combinations to fall-related hospital admissions.
The US Food and Drug Administration cleared UpDoc on December 23, 2025, as prescription software for adults with type 2 diabetes. Its chat interface collects patient data, while insulin instructions follow clinician-set treatment parameters.
A Taipei pharmacists' group and a private health association are expanding a program that links community pharmacies with clinics and corporate sponsors. The initiative proposes foot, bone and eye risk checks, but its promoters have not published test accuracy, referral completion or health-outcome data.
A survey of organizations funded by the US President's Emergency Plan for AIDS Relief linked grant terminations to the closure of more than 1,700 HIV service sites. The findings dominated the AIDS 2026 conference in Rio de Janeiro as delegates assessed whether damaged treatment and prevention networks can be rebuilt.
A 2024 systematic review found that explainable AI increased clinicians' trust in five of 10 empirical studies, while two reported mixed effects. A COVID-19 drug-repurposing project shows how an inspectable workflow can support expert review, but explanations do not establish clinical validity.
A 2026 evidence review found that oral NMN changes NAD-related biomarkers, while its effects on health and physical function remain inconsistent. Taiwan also bars food advertising from claiming medical efficacy, making product legality a separate question from clinical benefit.
Taiwan Health Nexus began operations on January 9, 2026, with plans to connect health records held by separate institutions for AI and research. Its public claims address interoperability, but evidence on consent, oversight and commercial reuse remains limited.
US regulators updated two software policies in January 2026, clarifying when low-risk wellness products and some clinical decision-support functions fall outside full device oversight. Taiwan requires qualifying AI medical software to enter its device-registration system, while the European Union layers high-risk AI obligations onto existing product rules.
